“Study validates Chronix Biomedical’s serum DNA blood tests for early, accurate detection of breast cancer (News-Medical-Net)” plus 1 more |
| Posted: 09 Mar 2010 05:11 AM PST Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests for the early and accurate detection of breast cancer. The Chronix tests detect the circulating DNA that is released into the blood stream by damaged and dying cells. A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseases—changes that can be used to identify disease processes at an early stage and to track responses to treatment. This new study shows that the Chronix approach was able to detect invasive breast cancer with high diagnostic sensitivity and specificity, even at the earliest stage when tumors are very small. The findings are published in the current online edition of Molecular Cancer Research.
"This study supports the potential of an entirely new approach to identifying cancer at its earliest stages when therapies may be most effective," said William M. Mitchell, M.D., Ph.D., Professor of Pathology at Vanderbilt University School of Medicine and a co-author of the study. "The promising diagnostic sensitivity and specificity achieved in this study further confirm the value of circulating DNA for disease detection and suggest that laboratory tests using this approach may have the potential both to screen large populations for cancer before symptoms appear and to monitor patients for the recurrence of cancer once treated." In the study, researchers applied advanced analytical techniques developed by Chronix to identify genomic DNA associated with breast cancer that was released into the bloodstream of women known to have breast cancer but was not present in healthy women or in patients with other medical conditions. Using the Chronix method, breast cancer was accurately detected at a diagnostic specificity level of 95% with a calculated sensitivity of 90%. Although not directly comparable, for reference it is useful to note that data from a large study of U.S. mammography screening programs reported an overall specificity of 92.3% and sensitivity of 75%, with lower figures for some populations such as younger women. "These positive data further validate the premise underlying the Chronix approach, showing that DNA circulating in the serum can be used to detect disease at its earliest stages with high levels of accuracy," said Howard Urnovitz, Ph.D., Chief Executive Officer of Chronix. "We have now been able to translate these research findings into a diagnostic assay that is initially suitable for use in clinical cancer research applications, and look forward to rapidly advancing both the breast cancer program and our pipeline of tests for other cancers and life threatening conditions." Source Chronix Biomedical
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Posted: 09 Mar 2010 05:41 AM PST TechniScan, Inc. (OTC Bulletin Board: TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated breast ultrasound imaging system, today announced that it has commenced phase two of its grant study at the University of California, San Diego (UCSD) Moores Cancer Center. TechniScan's Warm Bath Ultrasound (WBU™) system is designed to capture three-dimensional images of the breast as a woman lies prone on a table and state-of-the- art ultrasound technology is used in a warm water tank to capture images of the breast anatomy. The Moores UCSD Cancer Center is a National Cancer Institute (NCI) designated comprehensive cancer center with scientists and clinicians focused on developing the next generation of cancer therapies and cures. The TechniScan Warm Bath Ultrasound™ system investigations will be conducted with Michael P. Andre, Ph.D., Professor of Radiology, and breast radiologists Dr. Linda Olson and Dr. Haydee Ojeda-Fournier. Funded by a NCI Small Business Innovation Research Grant (SBIR) from the National Institute of Health, the study will involve approximately 130 women with various types of breast lesions. Major objectives of the 12-month study will be to compare WBU™ to conventional breast sonography and to examine the WBU™ system's ability to differentiate between normal, benign and malignant breast tissue. "We are excited to begin this new phase in the development of WBU™; it marks a genuine milestone in which our work may be translated to the front lines of the clinical world, " said Andre. Researchers involved in the study will also utilize TechniScan's groundbreaking imaging network, which provides them with the ability to archive, store, and retrieve WBU™ images and relevant medical records and to collaborate with other researchers at sites in Freiburg, Germany, Salt Lake City and Rochester, Minnesota. "Our vision is to begin to create a database of thousands of breast images and related data," said Dave Robinson, chief executive officer at TechniScan, Inc. "With complete anonymity, women may contribute their mammograms, breast MRI's and WBU™ images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. TechniScan's imaging network will also allow timely and efficient collaboration of patient's records for her medical team's use. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system." SOURCE TechniScan, Inc.Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Yahoo! News Search Results for Study Techniques To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment